Health disorders in women can be caused by many abnormalities in the body...
- FDA accelerated review denial is a blow to Spectrum’s poziotinib
- New drugs and therapeutic options help the immune system fight cancer
- Roche’s Tecentriq threatens BMS’ Opdivo in small cell lung cancer market
- The challenges of using stem cells in neurology
- Another BACE inhibitor fails in phase III trials
Clinically Relevant Mesenchymal Stem Cell Populations For Research
Renovos offers unique bone marrow mesenchymal stem cells (MSC), which have been isolated from patients with osteoarthritis for research purposes.
Stem Cells Sourced from Healthy and Diseased Donors
Caltag Medsystems specialises in procuring haematopoietic cells collected from healthy and diseased donors. Its suppliers are able to isolate and purify haematopoietic cells from a variety of tissues, including peripheral blood, mobilised peripheral blood, bone marrow and cord blood.
Validated Metal Analysis Results for Injectable-Grade Platform Excipients
Sucrose, trehalose, mannitol and maltose are four of the most commonly utilised carbohydrates for protein stabilisation in drug formulations.
February’s top news stories
Eidos Therapeutics commenced a pivotal Phase III clinical trial of its investigational small molecule AG10 for the treatment of transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM), and Immatics is set to study its investigational therapy IMA101 in combination with Roche’s Tecentriq (atezolizumab) drug for the treatment of solid cancers. Drugdevelopment-technology.com wraps up key headlines from February 2019.
January’s top news stories
Janssen Pharmaceutical Companies of Johnson & Johnson unblinded the Phase III TITAN trial investigating Erleada (apalutamide) in combination with androgen deprivation therapy (ADT) for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).
Customised R&D Services
AntalGenics offers the technology and knowledge required for the management of a wide variety of active ingredient formulation. Its research and development (R&D) capabilities provide high-quality design and development activities to meet the client's requirements.
Eligen® Technology Mechanism of Action
Emisphere's Eligen® Technology binds a delivery agent with a therapeutic compound without alternation. This process occurs when both agent and compound are in close proximity.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.